Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Glycosylated haemoglobin, Hypersensitivity, Pain in extremity, Pruritus
Clinical narrative: color was pink/my upper right arm sported a large pink; the arm was red and extremely itchy(redness was about 5 inches tall and 3 inches wide, like an oval)/large red/ itchy and turned bright red; delayed reaction; the right arm was itchy/itchy patch with rasg; Hypersensitivity reaction; Rash Local/itchy patch with rash; first day the site was slightly sore; soreness in the arm; This case was initially received via an unknown source (no reference has been entered for a health authority or license partner) on 02-Feb-2021. The most recent information was received on 29-Jun-2021 and was forwarded to Moderna on 29-Jun-2021.    This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (soreness in the arm), SKIN REACTION (delayed reaction), PRURITUS (the right arm was itchy/itchy patch with rasg), ERYTHEMA (the arm was red and extremely itchy(redness was about 5 inches tall and 3 inches wide, like an oval)/large red/ itchy and turned bright red) and VACCINATION SITE DISCOLOURATION (color was pink/my upper right arm sported a large pink) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 022M20A and 042L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included Cancer and Breast cancer. Concurrent medical conditions included Hyperlipidaemia (Taking medicine for cholesterol), Diabetes mellitus (Well controlled.) since 1993 and Trigeminal neuralgia. Concomitant products included LETROZOLE for Breast cancer, CANAGLIFLOZIN (INVOKANA [CANAGLIFLOZIN]), SAXAGLIPTIN (ONGLYZA [SAXAGLIPTIN]) and METFORMIN for Diabetes, TOPIRAMATE for Trigeminal neuralgia, BETAMETHASONE DIPROPIONATE, CLOTRIMAZOLE (LOTRISONE) for an unknown indication.   On 20-Jan-2021 at 11:30 AM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 20-Jan-2021, the patient experienced PAIN IN EXTREMITY (soreness in the arm). On 28-Jan-2021, the patient experienced SKIN REACTION (delayed reaction), PRURITUS (the right arm was itchy/itchy patch with rasg) and HYPERSENSITIVITY (Hypersensitivity reaction). 28-Jan-2021, the patient experienced RASH (Rash Local/itchy patch with rash) and VACCINATION SITE PAIN (first day the site was slightly sore). On 29-Jan-2021, the patient experienced ERYTHEMA (the arm was red and extremely itchy(redness was about 5 inches tall and 3 inches wide, like an oval)/large red/ itchy and turned bright red). On 01-Feb-2021, the patient experienced VACCINATION SITE DISCOLOURATION (color was pink/my upper right arm sported a large pink). The patient was treated with HYDROCORTISONE ongoing from 29-Jan-2021 for Itching, at a dose of 1 % four times per day. On 22-Jan-2021, PAIN IN EXTREMITY (soreness in the arm) had resolved. On 29-Jan-2021, VACCINATION SITE PAIN (first day the site was slightly sore) had resolved. On 02-Feb-2021, SKIN REACTION (delayed reaction), PRURITUS (the right arm was itchy/itchy patch with rasg), ERYTHEMA (the arm was red and extremely itchy(redness was about 5 inches tall and 3 inches wide, like an oval)/large red/ itchy and turned bright red) and VACCINATION SITE DISCOLOURATION (color was pink/my upper right arm sported a large pink) had resolved. At the time of the report, HYPERSENSITIVITY (Hypersensitivity reaction) and RASH (Rash Local/itchy patch with rash) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Glycosylated haemoglobin: 5.5 (normal) 5.5.         Other concomitant medications include Medication for Cholesterol.   Most recent FOLLOW-UP information incorporated above includes: On 29-Jun-2021: Updated patient demographics, Medical history, Lab data, Updated vaccine facility information, added Concomitant medication and updated treatment medication, added new events. On 02-Jul-2021: Follow-up Information received on 02-JUL-2021 contains No New Information